Compare Ascendis Pharma A/S (ASND) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Manulife Financial Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Manulife Financial Corporation trades at $41.29 (market cap $68.50B). The key difference: Manulife Financial Corporation is far larger — about 3.9× Ascendis Pharma A/S's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MFC | |
|---|---|---|
Market Cap | $17.74B | $68.50B |
Sector | Health | Financials |
52-Week High | $277.18 | $41.49 |
52-Week Low | $163.32 | $29.90 |
Enterprise Value | $18.11B | $65.07B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Manulife Financial (MFC) trades at $41.29, down 0.48% with a bullish technical outlook. The stock shows solid fundamentals with revenue growth to $53.01B in 2025 and net income of $5.78B, though Q1 2026 earnings missed expectations. Analyst consensus is strongly bullish with 57% buy ratings, supported by positive AI developments and dividend payments.
MFC presents a compelling investment case with strong profitability metrics (ROE 13.14%) and reasonable valuation (P/E 16.89). Key risks include regulatory scrutiny in Hong Kong and wealth management outflows. The company's AI leadership and Asia growth provide upside potential, though investors should monitor execution on recent strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
